Graves Adrienne L 4

What Happened Adrienne L. Graves, a director of Opus Genetics, was granted 24,367 restricted stock units (RSUs) on April 20, 2026. The Form 4 reports the acquisition at $0.00 per share (award/grant), i.e., no cash was paid at grant. This transaction is an award of equity rather than an open‑market purchase or sale.

Key Details

• Transaction date: 2026-04-20 (reported on Form 4 filed 2026-04-22).
• Transaction type/code: A — Grant/Award (restricted stock units).
• Shares/units granted: 24,367 RSUs. Price reported: $0.00; acquisition value: $0.
• Shares owned after transaction: Not specified in the provided filing.
• Footnote: RSUs vest upon the earlier of the one‑year anniversary of the grant or the day prior to the issuer’s next annual meeting, subject to continued service (per footnote F1).
• Timeliness: Form 4 filed two days after the grant date; appears to be timely (no late‑filing flag shown).

Context RSUs represent a right to receive common stock in the future if and when they vest; no shares were transferred at grant. Vesting conditions and continued service requirements determine when (or whether) these units convert into actual shares that the insider could sell. Awards are common for director and employee compensation and do not by themselves indicate a purchase or sale decision.